mTOR inhibitor

Rapamycin (Sirolimus)

Rapamycin (sirolimus) has a label mean terminal half-life of about 62 ± 16 hours in stable renal transplant patients; the app lists 62 hours.1

Emerging evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Rapamycin (Sirolimus) after one dose: 50% at ~62 h, 25% at 124 h, 12.5% at 186 h.

Drawn from the half-life in the app's model, ~62 h. The model's figures

Sirolimus, also called rapamycin, is described on its US label as "an mTOR inhibitor immunosuppressant" indicated for preventing organ rejection in patients aged 13 years or older who receive renal transplants.1 The same label lists a second use, in patients with lymphangioleiomyomatosis (LAM), and gives 1999 as the initial US approval year.1 The app lists a different use: a once-weekly oral dose of 5 to 8 mg, which the app's notes describe as pulsed dosing for longevity and distinct from daily transplant dosing.1 The label lists no longevity or healthy-ageing use.1

The app grades the evidence as emerging. A 2025 review by Hands and colleagues in Aging concluded that "the data in humans has yet to establish that rapamycin, or its analogues, is an effective seno-therapeutic to delay aging in healthy older adults".2 The review reports no conflicts of interest and states that "No funding was solicited in the course of this paper".2 The animal evidence comes from mice: Harrison and colleagues, in Nature in 2009, reported that rapamycin "extends median and maximal lifespan of both male and female mice when fed beginning at 600 days of age".3 That mouse result is not a result in people.3

The label states that in cells sirolimus "binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex".1 It continues that the complex "binds to and inhibits the activation of the mammalian target of rapamycin (mTOR), a key regulatory kinase".1 According to the label, this inhibition "suppresses cytokine-driven T-cell proliferation", and the complex has "no effect on calcineurin activity".1 The PEARL trial authors describe rapamycin as an inhibitor of mTORC1 that "is known to also impact mTORC2 in certain contexts", and propose that partial mTORC1 inhibition is "hypothesized" to mediate lifespan effects; this is the authors' hypothesis, not a result of the trial.6

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~62 h
Bioavailability
15%
Typical dose
5–8 mg/week
Route
Oral
Time to peak
~2 h

The app's figures are shown beside what the label and studies report. The label's figures come from renal transplant patients and healthy volunteers taking sirolimus daily or as a single dose, not from the once-weekly regimen in the app's dose range.

Table 3.1Half-life and pharmacokinetics5 rows
ParameterApp's figureReported in the sources
Half-life~62 hMean ± SD terminal elimination half-life of about 62 ± 16 hours after multiple dosing in stable renal transplant patients (label); an estimated terminal half-life of 68.9 ± 13.6 hours in 13 patients with early-stage Alzheimer's disease on weekly rapamycin, calculated from sparse samples across two dosing occasions1,4
Bioavailability15%About 14% after the oral solution, with the tablet about 27% higher relative to the solution and the two forms not bioequivalent (label)1
Time to peak~2 hMean times to peak concentration of approximately 1 hour in healthy subjects and 2 hours in renal transplant patients after the oral solution (label)1
Volume of distributionNot listedMean (Vss/F) of 12 ± 8 L/kg (label)1
Protein bindingNot listedApproximately 92% bound to human plasma proteins (label)1

The label adds that the mean blood-to-plasma ratio was "36 ± 18" in stable renal allograft patients, "indicating that sirolimus is extensively partitioned into formed blood elements".1 Sirolimus is "a substrate for both CYP3A4 and P-gp", and in the label's interaction studies ketoconazole raised sirolimus Cmax and AUC 4.3-fold and 10.9-fold, while erythromycin raised them 4.4-fold and 4.2-fold.1 In healthy subjects, a high-fat meal increased mean total exposure (AUC) "by 23 to 35%, compared with fasting".1

Wallgren and colleagues (Karolinska Institutet, GeroScience, 2026) gave 7 mg weekly to 11 patients with early-stage Alzheimer's disease, and 2 mg and 4 mg to one patient each, for 26 weeks in an open-label pilot.4 At the 7 mg dose, whole-blood concentration before dosing was 1.17 ± 0.44 ng/mL and 1 hour after dosing 26.73 ± 10.74 ng/mL.4 The authors report that "Blood concentrations at Cmin were below immunosuppressive levels in all participants".4 One further participant, a man, "did not tolerate the study drug due to nausea" and was excluded two weeks after starting; the 2 mg and 4 mg doses were used after vertigo in one participant and chronically elevated aspartate transaminase in another, and "No serious adverse events were observed during the trial".4 The authors declare no competing interests, and funding came from a Longevity Impetus grant from the Norn Group and several Swedish foundations.4

Compounded and generic forms

A retrospective registry study sponsored by AgelessRx (NCT06550271, 67 participants) compared compounded rapamycin at 5, 10 or 15 mg once weekly with generic rapamycin at 2, 3, 6 or 8 mg once weekly, with blood rapamycin level as the focus.5 The registry entry read for this compound lists no results; the PEARL authors state that compounded rapamycin "did indeed have approximately ⅓ the concentration in blood after 24 hrs relative to commercial" and that "equivalent effective doses for compounded forms are approximately 66% less".6

Level over 6 weeks

Interval between doses

Level, as a share of the peak after one 100 mg dose

As studied: daily dosing in the label (2 mg/day for LAM)1, once weekly, as in PEARL, RAPA-EX-01 and the Wallgren study6.

An illustration from a pharmacokinetic model using a half-life of 62 hours (2.58 days). It is not a measured level or a suggested dose.

4

Human studies

Searches of PubMed and ClinicalTrials.gov returned three randomised, placebo-controlled trials of rapamycin or sirolimus in older adults without a transplant indication (Kraig 2018, PEARL 2025, RAPA-EX-01 2026), none with lifespan or mortality as its outcome.6,7,8

Table 4.1Human studies5 rows
Study and yearDesignPeopleDose and lengthMain result
Moel and colleagues, PEARL, Aging 20256Decentralised, double-blind, placebo-controlled randomised trial (NCT04488601); AgelessRx authors and support6114 completers aged 50 to 85 years in good health or with stable chronic disease: 40 on 5 mg, 35 on 10 mg, 39 on placebo; 35.1% women6Compounded rapamycin 5 mg or 10 mg once weekly, or placebo, for 48 weeks6Primary outcome, visceral adiposity, did not change significantly (p = 0.942); lean tissue mass and self-reported pain improved significantly in the subgroup of 8 women on 10 mg (secondary outcomes); adverse events similar across groups, with more GI symptoms on rapamycin; 11 participants discontinued before completion6
Kraig and colleagues, Experimental Gerontology 20187Randomised, placebo-controlled pilot (NCT02874924); NIH-supported725 generally healthy adults aged 70 to 95 years; 11 rapamycin and 14 placebo completed at least 8 weeks7Rapamycin 1 mg daily or placebo, at least 8 weeks7Decrements in haemoglobin, haematocrit and other red-cell measures on rapamycin; no change in glucose tolerance testing, cognition or physical performance measures; immune measures largely unchanged7
Stanfield and colleagues, RAPA-EX-01, Journal of Cachexia, Sarcopenia and Muscle 20268Randomised, double-blind, placebo-controlled exploratory trial, with a home exercise programme in both arms; crowdfunded840 sedentary adults aged 65 to 85 years (mean 72.2; 47.5% female)8Sirolimus 6 mg or placebo once weekly for 13 weeks8Chair-stand difference of -2.13 repetitions (95% CI -4.61 to 0.34; p = 0.089) in the intention-to-treat analysis; 99 adverse events on sirolimus against 63 on placebo, with one possibly drug-related serious event (pneumonia)8
Wallgren and colleagues, GeroScience 20264Open-label pharmacokinetic pilot (NCT06022068)413 patients with early-stage Alzheimer's disease47 mg weekly (11 patients), 2 mg or 4 mg (one each), 26 weeks4Estimated terminal half-life 68.9 ± 13.6 hours; pre-dose concentrations below immunosuppressive levels; no serious adverse events4
Singh and colleagues, Journal of Frailty and Aging 20169Pilot study in older adults undergoing cardiac rehabilitation (NCT01649960); no comparator group is described in the source text913 patients with coronary artery disease, median age 73.9 ± 7.5 years, 12 men9Rapamycin 0.5 mg (6), 1.0 mg (6) or 2 mg (1) daily for 12 weeks; serum rapamycin <6 ng/ml9Serum interleukin-6 decreased (2.6 vs 4.4 pg/ml) and MMP-3 increased (26 vs 23.5 ng/ml); "no improvement in frailty with rapamycin was noted"9

Deeper analysis: PEARL

Moel and colleagues (AgelessRx, Ann Arbor, Michigan) reported PEARL in Aging in 2025 as a 48-week, single-centre, decentralised trial registered as NCT04488601.6 Participants were recruited through the AgelessRx online medical platform, and 114 completed the study while 11 discontinued (6 on placebo, 3 on 10 mg, 2 on 5 mg).6 Women made up 35.1% of participants, with 8 women in the 10 mg group, 17 in the 5 mg group and 15 on placebo.6 The primary outcome was visceral adiposity by DXA scan; the secondary outcomes were blood biomarkers, lean tissue and bone mineral content.6 The primary outcome did not change significantly (ηp2 = 0.001, p = 0.942).6 Lean tissue mass and self-reported pain improved significantly for women on 10 mg, a subgroup of 8 women, and the authors state that the 10 mg compounded dose is "equivalent to ~3.33 mgs of generic Sirolimus".6 Self-reported general health improved on 5 mg, and emotional well-being improved on 5 mg and also on placebo: "improvements in Emotional Well-being were only seen for 5mg rapamycin users and placebo groups after 48 weeks".6 WOMAC scores showed no significant change in any group.6 On safety, non-severe adverse events totalled 117 on 10 mg, 116 on 5 mg and 122 on placebo, serious adverse events numbered 1, 2 and 3 respectively, and gastrointestinal symptoms were reported by 8, 7 and 4 participants.6 The authors note "a single report of anemia in the entire study, in a participant in the 5 mg treatment group", which "resolved with treatment (blood transfusion)".6 The authors' conclusion reads: "Low-dose, intermittent rapamycin administration over 48 weeks is relatively safe in healthy, normative-aging adults".6 Their stated limitations include that "findings are limited by the small relative cohort size", that "adherence to the once-weekly dosing schedule was based largely on self-report", and that the cohort had "relatively few women and predominantly health-conscious participants".6 The authors state that the trial was temporarily paused while they explored, in an independent cohort, whether the compounded formulation had reduced bioavailability relative to commercial formulations, and that compounded rapamycin was subsequently found to have approximately one third the blood concentration after 24 hours.6 Funding "came primarily from donors via a Lifespan.io crowdfunding effort", with "Administrative and trial support, article publishing charges, and other fees" provided by AgelessRx; the conflict statement says that "GH, VL, AN, MM, SM, AI, and SZ are employees and shareholders of AgelessRx", which covers all seven authors.6

Deeper analysis: Kraig pilot trial

Kraig and colleagues (University of Texas Health Science Center at San Antonio, Experimental Gerontology, 2018) randomised 25 generally healthy adults aged 70 to 95 years to 1 mg rapamycin or placebo daily; three withdrew, and 11 on rapamycin and 14 controls completed at least 8 weeks.7 The study drug was Rapamune "obtained through either Pfizer, Inc. or its subsidiary, Greenstone LLC", and the record lists NIH extramural research support.7 Peak blood concentrations in the rapamycin group "varied from 2.5–11.8 ng/ml".7 Five subjects reported potential adverse effects: facial rash in 1, stomatitis in 1 and gastrointestinal issues in 2 on rapamycin, and stomatitis in 1 on placebo.7 Rapamycin was associated with statistically significant decrements in haemoglobin, haematocrit, red blood cell count, RDW, MCV and MCH, and the authors state that "None of these changes manifested clinically significant effects during the short duration of this study".7 Oral glucose tolerance tests "revealed no RAPA-induced change in blood glucose concentration, insulin secretion, and insulin sensitivity".7 The authors call for "a trial with a larger sample size and longer treatment duration", and note that "Due to the small sample size in this pilot study, it was not possible to statistically control for the drugs being taken by an individual subject."7

Deeper analysis: RAPA-EX-01

Stanfield and colleagues (Aotearoa Clinical Trials Trust, Auckland; Journal of Cachexia, Sarcopenia and Muscle, 2026) tested whether once-weekly sirolimus 6 mg altered gains from a home exercise programme, registered as ACTRN12624000790549.8 Forty sedentary adults aged 65 to 85 years took sirolimus or placebo once weekly for 13 weeks; the primary outcome was the change in 30-second chair-stand repetitions.8 Both groups improved, and the intention-to-treat difference was -2.13 repetitions (95% CI -4.61 to 0.34; p = 0.089).8 The prespecified complete-case analysis (16 sirolimus, 19 placebo) gave -2.46 repetitions (95% CI -4.87 to -0.06; p = 0.045) and the per-protocol analysis (15 sirolimus, 16 placebo) gave -3.44 repetitions (95% CI -5.86 to -0.99; p = 0.007), both favouring placebo.8 Six-minute walk distance (-4.87 m, p = 0.706) and grip strength (-1.13 kg in the summary, -1.19 kg in the results text; p = 0.344) also favoured placebo without reaching significance.8 Seventeen participants (85%) in each arm reported at least one adverse event, with 99 events on sirolimus and 63 on placebo (incidence rate ratio 1.57; 95% CI 0.86–2.87; p = 0.14), and events judged possibly or probably drug-related occurred in 35% on sirolimus against 15% on placebo.8 Five participants in the sirolimus arm and three in the placebo arm discontinued the intervention early, and their available data were included in the intention-to-treat analysis.8 The authors conclude that the regimen "did not enhance, and in sensitivity analyses, it may have modestly attenuated short-term functional improvements from a home exercise programme in older adults".8 They state that "we did not perform muscle biopsies or pharmacokinetic monitoring", so their mechanistic explanation "remains inferential".8 The trial "was funded entirely by public donations (crowdfunding) facilitated by Lifespan.io and VitaDAO", and the authors declare "no conflicts of interest regarding the study drug or intervention", while disclosing that the first author earns YouTube advertising revenue and founded a dietary supplement company.8

5

Doses reported in studies and on labels

The app lists a typical range of 5 to 8 mg per week.1 The label gives sirolimus once daily by mouth, and its doses below apply to transplant and LAM patients; the study doses are from the trials above.

Table 5.1Doses reported in studies and on labels9 rows
SettingDose and scheduleComparator, length and nReference
Label: renal transplant, low to moderate immunologic riskLoading dose of 6 mg, then a daily maintenance dose of 2 mg, with cyclosporine and corticosteroidsConcentration-guided; no comparator in the label text readSirolimus label1
Label: renal transplant, high immunologic riskLoading dose of up to 15 mg on day 1, then 5 mg/day, with cyclosporine and corticosteroidsConcentration-guided; first 12 monthsSirolimus label1
Label: lymphangioleiomyomatosisInitial 2 mg/day; target whole-blood trough 5 to 15 ng/mLMedian trough 6.8 ng/mL (IQR 4.6 to 9.0; n = 37) after 3 weeks on 2 mg/daySirolimus label1
PEARLCompounded rapamycin 5 mg or 10 mg once weekly, oralPlacebo; 48 weeks; 40, 35 and 39 completersMoel 20256
RAPA-EX-01Sirolimus 6 mg (3 × 2 mg tablets) once weekly, oralMatched placebo; 13 weeks; 20 per armStanfield 20268
Wallgren pilot7 mg once weekly (2 mg or 4 mg in one patient each), oral Rapamune tabletsNo comparator; 26 weeks; 13 patientsWallgren 20264
Kraig pilot1 mg daily, oralPlacebo; at least 8 weeks; 11 rapamycin and 14 placebo analysedKraig 20187
Singh pilot0.5 mg (6 patients), 1.0 mg (6) or 2 mg (1) daily, oralNo comparator; 12 weeks; 13 patientsSingh 20169
Registry cohort NCT06550271Compounded 5, 10 or 15 mg once weekly; generic 2, 3, 6 or 8 mg once weeklyRetrospective, 67 participants; sponsor AgelessRxRegistry entry5

The label's boxed warning states that "Increased susceptibility to infection and the possible development of lymphoma and other malignancies may result from immunosuppression".1 The label lists adverse reactions occurring in at least 30% of renal transplant patients, including peripheral edema, hypertriglyceridemia, hypertension, hypercholesterolemia, creatinine increased, anemia and thrombocytopenia.1 In the LAM study (89 patients, 46 on sirolimus), reactions in at least 20% and more often than on placebo included stomatitis, diarrhea, nausea, acne and peripheral edema.1 Post-marketing reports in transplant patients include "Hepatotoxicity, including fatal hepatic necrosis, with elevated sirolimus trough concentrations".1 These label data come from transplant and LAM patients on daily dosing; the label does not describe once-weekly use.1 In the weekly-dose trials, PEARL reported similar adverse event counts across arms with more gastrointestinal symptoms on rapamycin, whereas RAPA-EX-01 reported more adverse events on sirolimus (99 against 63) and one possibly drug-related serious adverse event (pneumonia).6,8 In the small daily 1 mg Kraig trial, reports were facial rash, stomatitis and gastrointestinal issues on rapamycin.7

The app lists four markers to monitor: lipid panel, fasting glucose, CBC and liver enzymes (ALT, AST). On lipids, the label reports hypercholesterolemia in 43 to 46% and hypertriglyceridemia in 45 to 57% of patients on sirolimus, against 23% for each on placebo controls, and states that any patient given sirolimus is to be monitored for hyperlipidemia.1 The label also says that in these trials "the number of patients was too small and duration of follow-up too short to evaluate the long-term impact of sirolimus on cardiovascular mortality".1 In PEARL, "changes in blood biomarkers remained within normal ranges", although red blood cells rose in the 5 mg group, BUN rose in men on 10 mg, and men on 5 mg showed "small Hemoglobin A1C increases at 48 weeks" with no significant change in glucose or insulin.6 In the Kraig trial (1 mg daily, 8 weeks or more) the CBC showed decrements in erythrocyte measures on rapamycin, with no change in glucose tolerance testing.7 In RAPA-EX-01, the laboratory table lists an adjusted difference (intention-to-treat) for total cholesterol of 0.49 mmol/L (95% CI 0.15821 to 0.81531; p = 0.004) and for ALT of -0.26 U/L (95% CI -6.4278 to 6.2023; p = 0.94); the text also reports LDL cholesterol +0.32 mmol/L (p = 0.036) and HbA1c +1.74 mmol/mol (p = 0.030) compared with placebo, which the authors describe as "statistically significant but clinically modest shifts in the sirolimus arm".8

8

Regulatory and anti-doping status

The sirolimus label gives 1999 as the initial US approval year, for renal transplant rejection prophylaxis in patients aged 13 years or older and for LAM.1 The label states that "The safety and efficacy of sirolimus as immunosuppressive therapy have not been established in liver or lung transplant patients, and therefore, such use is not recommended".1 Weekly low-dose use for longevity is not a labelled indication in the label read, and the app's notes describe it as off-label prescribing.1 The words sirolimus, rapamycin and mTOR do not occur in the retrieved text of the World Anti-Doping Agency's 2026 Prohibited List, and the metabolic modulators class (S4.4) lists other named substances; a later list was not checked.10

9

Storage and handling

The label for sirolimus tablets states "Store sirolimus tablets at room temperature between 68°F to 77°F (20°C to 25°C)" and to keep the bottle tightly closed.1

No trial of weekly rapamycin with lifespan, mortality or age-related disease incidence as its outcome was identified among the PubMed and ClinicalTrials.gov records retrieved for this compound. The Hands review concludes that the human picture "remains insufficient to affirm or negate the longevity and healthspan extending benefits attributed to rapamycin".2 The three randomised trials differ in dose (1 mg daily, 5 to 10 mg compounded weekly, 6 mg weekly), length (8 weeks or more, 13 weeks, 48 weeks) and population, and they reached different results on function and safety, so no single weekly regimen has a replicated effect in the records read.7,6,8 Equivalence between compounded and generic rapamycin rests on a registry cohort whose results were not available in the entry read, and on the PEARL authors' statement of approximately one third of the blood concentration.5,6 The Wallgren authors write that cerebrospinal fluid quantification "revealed methodological challenges due to analytical sensitivity limitations".4 The RAPA-EX-01 authors write that "the longer-term effects of combining sirolimus (rapamycin) with exercise, particularly with lower doses or less frequent administration, remain unknown".8

What is the half-life of rapamycin?

The label gives a mean terminal elimination half-life of about 62 ± 16 hours after multiple dosing in stable renal transplant patients, and the app lists 62 hours.1 A pilot in 13 patients with early-stage Alzheimer's disease on weekly rapamycin estimated 68.9 ± 13.6 hours.4

What is the bioavailability of rapamycin?

The label estimates the systemic availability of the oral solution at approximately 14%, and the app lists 15%.1 The tablet's mean bioavailability is about 27% higher than the solution's, and the two are not bioequivalent.1

How long does rapamycin take to reach its peak level?

The label gives mean times to peak concentration of approximately 1 hour in healthy subjects and 2 hours in renal transplant patients after the oral solution, and the app lists about 2 hours.1

Is rapamycin the same as sirolimus?

The two names refer to the same compound in the sources read, where the label uses sirolimus and the trials use either name.1,8

Is rapamycin banned by WADA?

Sirolimus, rapamycin and mTOR do not occur in the retrieved text of the WADA 2026 Prohibited List; a later list was not checked.10

Is rapamycin FDA approved for longevity?

The sirolimus label lists renal transplant rejection prophylaxis and lymphangioleiomyomatosis, not longevity.1

Does rapamycin extend lifespan in humans?

A 2025 review concluded that the human data "has yet to establish that rapamycin, or its analogues, is an effective seno-therapeutic to delay aging in healthy older adults".2 In mice, rapamycin fed from 600 days of age increased age at 90% mortality by 14% in females and 9% in males.3

What are the side effects of rapamycin?

The label lists peripheral edema, hypertriglyceridemia, hypertension and hypercholesterolemia among reactions in at least 30% of renal transplant patients, and a boxed warning on infection and malignancy risk from immunosuppression.1 In the 13-week RAPA-EX-01 trial of 6 mg weekly, 99 adverse events were reported on sirolimus against 63 on placebo.8

13

References

  1. Mylan Pharmaceuticals Inc. Sirolimus tablets and oral solution. US prescribing information, DailyMed record version 22, 2026. DailyMed label
  2. Hands JM, et al. What is the clinical evidence to support off-label rapamycin therapy in healthy adults? Aging (Albany NY) 2025. PMID 40778880
  3. Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009. PMID 19587680
  4. Wallgren HA, et al. Pharmacokinetic analysis of intermittent rapamycin administration in early-stage Alzheimer's Disease. GeroScience 2026. PMID 41046300
  5. AgelessRx. The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals. ClinicalTrials.gov NCT06550271. NCT06550271
  6. Moel M, et al. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Albany NY) 2025. PMID 40188830
  7. Kraig E, et al. A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. Exp Gerontol 2018. PMID 29408453
  8. Stanfield B, et al. Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA-EX-01 Randomised, Double-Blind, Placebo-Controlled Trial. J Cachexia Sarcopenia Muscle 2026. PMID 41985884
  9. Singh M, et al. Effect of Low-Dose Rapamycin on Senescence Markers and Physical Functioning in Older Adults with Coronary Artery Disease: Results of a Pilot Study. J Frailty Aging 2016. PMID 27883166
  10. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list